Differential c-Fos induction by different NMDA receptor antagonists with 
antidepressant efficacy: potential clinical implications

Inta, Dragos; Trusel, Massimo; Riva, Marco Andrea; Sprengel, Rolf; Gass, Peter

doi:10.1017/S1461145709990319

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potential clinical implications

MPS-Authors

/persons/resource/persons95439

Sprengel, Rolf
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

External Resource

http://ijnp.oxfordjournals.org/content/12/8/1133.full.pdf
(Any fulltext)

http://dx.doi.org/10.1017/S1461145709990319
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Inta, D., Trusel, M., Riva, M. A., Sprengel, R., & Gass, P. (2009). Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potential clinical implications. International Journal of Neuropsychopharmacology, 12(8), 1133-1136. doi:10.1017/S1461145709990319.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-115F-9

Abstract

Preclinical and clinical studies have shown that N-methyl-D-aspartate (NMDA) receptor antagonists can exert antidepressant effects. Thus, a single intravenous injection of ketamine, a non-competitive NMDA receptor antagonists, has been recently demonstrated to produce a rapid and relatively sustained antidepressant effect in patients. Therefore, the role of NMDA receptors and their signalling pathways for pathophysiology and therapy of depression are under intense research.